Helena Valta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Helena Valta has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Outi Mäkitie
Children’s Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
9 shared publications Hannu Jalanko
3 shared publications- Heidi Arponen
Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland
3 shared publications - Adel Bachour
Sleep Unit, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland
2 shared publications - Antti Mäkitie
University of Helsinki
2 shared publications - Janna Waltimo-Sirén
Department of Oral and Maxillofacial Diseases, University of Helsinki, P.O. Box 41, FI-00014 Helsinki, Finland
2 shared publications
Latest Publications
- Open Access
- 9 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (22)
PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia
Polypyrimidine tract-binding protein PTBP1 is a heterogeneous nuclear ribonucleoprotein primarily known for its alternative splicing activity. It shuttles between the nucleus and cytoplasm via partially overlapping N-terminal nuclear localization (NLS) and export (NES) signals. Despite its fundamental role in cell growth and differentiation, its involvement in human disease remains poorly understood. We identified 27 individuals from 25 families harboring de novo or inherited pathogenic variants — predominantly start-loss (89%) and, to a lesser extent, missense (11%) — affecting NES/NLS motifs. Affected individual presented with a syndromic neurodevelopmental disorder and variable skeletal dysplasia with disproportionate short-limbed short stature. Intellectual functioning ranged from normal to moderately delayed. Start-loss variants led to translation initiation from an alternative downstream in-frame methionine, resulting in loss of the NES and the first half of the bipartite NLS, and increased cytoplasmic stability. Start-loss and missense variants shared a DNA methylation episignature in peripheral blood and altered nucleocytoplasmic distribution in vitro and in vivo with preferential accumulation in processing bodies, causing aberrant gene expression but normal RNA splicing. Transcriptomic analysis of patient-derived fibroblasts revealed dysregulated pathways involved in osteochondrogenesis and neurodevelopment. Overall, our findings highlight a cytoplasmic role for PTBP1 in RNA stability and disease pathogenesis.
- 9 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (22)
Open AccessPTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia
Polypyrimidine tract-binding protein PTBP1 is a heterogeneous nuclear ribonucleoprotein primarily known for its alternative splicing activity. It shuttles between the nucleus and cytoplasm via partially overlapping N-terminal nuclear localization (NLS) and export (NES) signals. Despite its fundamental role in cell growth and differentiation, its involvement in human disease remains poorly understood. We identified 27 individuals from 25 families harboring de novo or inherited pathogenic variants — predominantly start-loss (89%) and, to a lesser extent, missense (11%) — affecting NES/NLS motifs. Affected individual presented with a syndromic neurodevelopmental disorder and variable skeletal dysplasia with disproportionate short-limbed short stature. Intellectual functioning ranged from normal to moderately delayed. Start-loss variants led to translation initiation from an alternative downstream in-frame methionine, resulting in loss of the NES and the first half of the bipartite NLS, and increased cytoplasmic stability. Start-loss and missense variants shared a DNA methylation episignature in peripheral blood and altered nucleocytoplasmic distribution in vitro and in vivo with preferential accumulation in processing bodies, causing aberrant gene expression but normal RNA splicing. Transcriptomic analysis of patient-derived fibroblasts revealed dysregulated pathways involved in osteochondrogenesis and neurodevelopment. Overall, our findings highlight a cytoplasmic role for PTBP1 in RNA stability and disease pathogenesis.
- Open Access
- 11 January 2021
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 22 (1) , 1-8
Positive airway pressure therapy for obstructive sleep apnea in patients with Osteogenesis imperfecta: a prospective pilot study
Background: Obstructive sleep apnea (OSA) is prevalent in individuals with Osteogenesis imperfecta (OI). To date, no study has investigated treatment of OSA in adult individuals with OI using positive airway pressure (PAP). This observational pilot study examined the adherence of adults with OI to treatment of OSA with PAP therapy, and the evolution of self-experienced sleepiness and depression symptoms before and after treatment.Methods: We included 20 patients, with a mean age of 51 years, who represented varying severity of OI and displayed an apnea and hypopnea index ≥ 5 /sleeping hour as recorded by an overnight polysomnography. PAP therapy was proposed to all patients. Epworth Sleepiness Scale (ESS) questionnaire to evaluate daytime sleepiness, and a validated self-rating depression questionnaire to identify possible depression, were completed prior to PAP therapy and repeated after a minimum of one year. The datasets supporting the conclusions of this article are included within the article.Results: From the 20 patients, 15 initiated PAP therapy, and two patients later interrupted it. The mean PAP follow-up period was 1230 days. At baseline, an abnormally high ESS score was reported by 29% of the respondents, and an abnormally high number of symptoms suggesting depression by 29%. Follow-up questionnaires were completed by 60% of the patients, of whom 83% were adherent to PAP treatment. ESS score and depression symptoms did not decrease significantly with PAP therapy.Conclusions: Patients with OI accepted well PAP therapy and remained compliant. Sleepiness and depression persisted unaltered despite good PAP adherence. These unexpectedly poor improvements in symptoms by PAP therapy may be due to subjective depression symptoms and the complexity of factors underlying persisting sleepiness in OI. Further research is needed to confirm this novel finding.
- 11 January 2021
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 22 (1) , 1-8
Open AccessPositive airway pressure therapy for obstructive sleep apnea in patients with Osteogenesis imperfecta: a prospective pilot study
Background: Obstructive sleep apnea (OSA) is prevalent in individuals with Osteogenesis imperfecta (OI). To date, no study has investigated treatment of OSA in adult individuals with OI using positive airway pressure (PAP). This observational pilot study examined the adherence of adults with OI to treatment of OSA with PAP therapy, and the evolution of self-experienced sleepiness and depression symptoms before and after treatment.Methods: We included 20 patients, with a mean age of 51 years, who represented varying severity of OI and displayed an apnea and hypopnea index ≥ 5 /sleeping hour as recorded by an overnight polysomnography. PAP therapy was proposed to all patients. Epworth Sleepiness Scale (ESS) questionnaire to evaluate daytime sleepiness, and a validated self-rating depression questionnaire to identify possible depression, were completed prior to PAP therapy and repeated after a minimum of one year. The datasets supporting the conclusions of this article are included within the article.Results: From the 20 patients, 15 initiated PAP therapy, and two patients later interrupted it. The mean PAP follow-up period was 1230 days. At baseline, an abnormally high ESS score was reported by 29% of the respondents, and an abnormally high number of symptoms suggesting depression by 29%. Follow-up questionnaires were completed by 60% of the patients, of whom 83% were adherent to PAP treatment. ESS score and depression symptoms did not decrease significantly with PAP therapy.Conclusions: Patients with OI accepted well PAP therapy and remained compliant. Sleepiness and depression persisted unaltered despite good PAP adherence. These unexpectedly poor improvements in symptoms by PAP therapy may be due to subjective depression symptoms and the complexity of factors underlying persisting sleepiness in OI. Further research is needed to confirm this novel finding.
- Open Access
- 29 December 2018
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 13 (1) , 231
Is sleep apnea underdiagnosed in adult patients with osteogenesis imperfecta? –a single-center cross-sectional study
Patients with Osteogenesis imperfecta (OI) suffer from increased bone fracture tendency generally caused by a mutation in genes coding for type I collagen. OI is also characterized by numerous co-morbidities, and recent data from questionnaire studies suggest that these may include increased risk for sleep apnea, a finding that lacks clinical evidence from cohort studies. In this cross-sectional study, 25 adults with OI underwent clinical otorhinolaryngology examination as well as overnight polysomnography to address the question. The participants were aged between 19 and 77 years, and ten of them had mild clinical OI phenotype, seven had a moderately severe phenotype, and eight had a severe phenotype. We found obstructive sleep apnea (apnea hypopnea index ≥5/h) in as many as 52% of the OI patients in the cohort. Unexpectedly, however, no correlation was present between sleep apnea and daytime sleepiness, experienced bodily pain, severity of OI, Mallampati score, or neck circumference. Seeing that the usual predictors showed no association with occurrence of sleep apnea, we conclude that obstructive sleep apnea may easily be left as an undetected disorder in individuals with OI. Recurrent nocturnal hypoxia due to episodes of apneas can even affect bone metabolism, thereby further aggravating bone fragility in patients with OI.
- 29 December 2018
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 13 (1) , 231
Open AccessIs sleep apnea underdiagnosed in adult patients with osteogenesis imperfecta? –a single-center cross-sectional study
Patients with Osteogenesis imperfecta (OI) suffer from increased bone fracture tendency generally caused by a mutation in genes coding for type I collagen. OI is also characterized by numerous co-morbidities, and recent data from questionnaire studies suggest that these may include increased risk for sleep apnea, a finding that lacks clinical evidence from cohort studies. In this cross-sectional study, 25 adults with OI underwent clinical otorhinolaryngology examination as well as overnight polysomnography to address the question. The participants were aged between 19 and 77 years, and ten of them had mild clinical OI phenotype, seven had a moderately severe phenotype, and eight had a severe phenotype. We found obstructive sleep apnea (apnea hypopnea index ≥5/h) in as many as 52% of the OI patients in the cohort. Unexpectedly, however, no correlation was present between sleep apnea and daytime sleepiness, experienced bodily pain, severity of OI, Mallampati score, or neck circumference. Seeing that the usual predictors showed no association with occurrence of sleep apnea, we conclude that obstructive sleep apnea may easily be left as an undetected disorder in individuals with OI. Recurrent nocturnal hypoxia due to episodes of apneas can even affect bone metabolism, thereby further aggravating bone fragility in patients with OI.
- Open Access
- 8 January 2018
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 19 (1) , 3
Fatigue and disturbances of sleep in patients with osteogenesis imperfecta – a cross-sectional questionnaire study
Persisting fatigue has been reported to be a common complaint by individuals with connective tissue disorders, including Osteogenesis imperfecta (OI). This controlled study evaluated in an adult OI population the subjective experience of fatigue, affecting daily life. Sleep disturbances and chronic pain were examined as hypothesized underlying factors. This cross-sectional study analyzed the answers of 56 OI patients and 56 matched healthy controls to a questionnaire, designed to evaluate levels of experienced fatigue and bodily pain, as well as the presence or absence of symptoms related to sleep disturbances or sleep apnea. The relationships between fatigue, pain, and sleep disturbances were evaluated with correlation analysis and regression analysis. Fatigue was reported by 96%, and daily pain by 87% of the individuals with OI. Notably, the level of fatigue was similarly experienced by patient respondents and controls. In total, 95% of the patients and 77% of the controls reported one to several sleep disturbance symptoms. These symptoms as well as previously diagnosed sleep apnea were statistically significantly more prevalent in the patient group than in the controls (p < 0.05). Likewise, the experienced bodily pain was statistically highly significantly more severe among the respondents with OI (p < 0.001), and correlated with the reported fatigue. In comparison with age-matched controls, adults with OI do not differ in experienced fatigue, unlike hypothesized. Therefore, sleep disturbances, which based on the frequency of reported related symptoms and previous sleep apnea diagnoses appear to be common in OI patients, may remain undiagnosed.
- 8 January 2018
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 19 (1) , 3
Open AccessFatigue and disturbances of sleep in patients with osteogenesis imperfecta – a cross-sectional questionnaire study
Persisting fatigue has been reported to be a common complaint by individuals with connective tissue disorders, including Osteogenesis imperfecta (OI). This controlled study evaluated in an adult OI population the subjective experience of fatigue, affecting daily life. Sleep disturbances and chronic pain were examined as hypothesized underlying factors. This cross-sectional study analyzed the answers of 56 OI patients and 56 matched healthy controls to a questionnaire, designed to evaluate levels of experienced fatigue and bodily pain, as well as the presence or absence of symptoms related to sleep disturbances or sleep apnea. The relationships between fatigue, pain, and sleep disturbances were evaluated with correlation analysis and regression analysis. Fatigue was reported by 96%, and daily pain by 87% of the individuals with OI. Notably, the level of fatigue was similarly experienced by patient respondents and controls. In total, 95% of the patients and 77% of the controls reported one to several sleep disturbance symptoms. These symptoms as well as previously diagnosed sleep apnea were statistically significantly more prevalent in the patient group than in the controls (p < 0.05). Likewise, the experienced bodily pain was statistically highly significantly more severe among the respondents with OI (p < 0.001), and correlated with the reported fatigue. In comparison with age-matched controls, adults with OI do not differ in experienced fatigue, unlike hypothesized. Therefore, sleep disturbances, which based on the frequency of reported related symptoms and previous sleep apnea diagnoses appear to be common in OI patients, may remain undiagnosed.
- 11 July 2017
- Published by Bioscientifica in Bone Abstracts
The abnormally high and heterogeneous bone matrix mineralization after childhood solid organ transplantation is not further increased by bisphosphonate treatment
Background: Chronic renal, liver and heart failure in children associate with multiple skeletal complications. Increased fracture incidence often persists after transplantation and might be related to alterations in bone material properties. Moreover, it is not clear whether bisphosphonate therapy (BP) alters bone matrix mineralization in these patients. Methods: In the present study we evaluated bone mineralization density distribution (BMDD) by quantitative backscattered electron imaging (qBEI) in transiliac bone biopsies obtained from kidney (n=9), liver (n=9) and heart (n=5) transplant recipients (aged 7.6–19.7 years, 6.0±5.6 years post-transplantation) with suspected osteoporosis and in two kidney and four liver recipients after 2 years’ BP treatment (paired biopsies). Furthermore, we related the BMDD parameters with clinical and bone histomorphometric outcomes. Results: Compared to healthy children, the qBEI analyses in transplant recipients prior BP revealed an increase in the most frequently occurring calcium concentration (+2.9%, P=0.001;+3.5%, P=0.014), in the portion of fully mineralized bone (fivefold; 10-fold, both PPP=0.47; cortical bone: 21.4% after BP vs 22.0% prior BP, P=0.56) except in one patient with abnormally low bone matrix mineralization and increased indices of bone turnover that normalized after treatment. Accumulation of mineralized cartilage was observed in the bone tissue after BP. Conclusions: The abnormally high bone matrix mineralization in transplant recipients, consistent with serum and histomorphometric outcomes, indicates a history of low bone turnover with accumulation of fully mineralized bone packets. The increased heterogeneity of mineralization suggests local alterations in mineralization kinetics. This may be linked to dysfunctional osteocytes that accumulate within the bone matrix during organ failure and concomitant glucocorticoid and immunosuppressive medication. BP does not further increase bone matrix mineralization, however the presence of mineralized cartilage warrants further clarifications. The authors have no conflicts of interest. Disclosure: The authors declared no competing interests.
- 11 July 2017
- Published by Bioscientifica in Bone Abstracts
The abnormally high and heterogeneous bone matrix mineralization after childhood solid organ transplantation is not further increased by bisphosphonate treatment
Background: Chronic renal, liver and heart failure in children associate with multiple skeletal complications. Increased fracture incidence often persists after transplantation and might be related to alterations in bone material properties. Moreover, it is not clear whether bisphosphonate therapy (BP) alters bone matrix mineralization in these patients. Methods: In the present study we evaluated bone mineralization density distribution (BMDD) by quantitative backscattered electron imaging (qBEI) in transiliac bone biopsies obtained from kidney (n=9), liver (n=9) and heart (n=5) transplant recipients (aged 7.6–19.7 years, 6.0±5.6 years post-transplantation) with suspected osteoporosis and in two kidney and four liver recipients after 2 years’ BP treatment (paired biopsies). Furthermore, we related the BMDD parameters with clinical and bone histomorphometric outcomes. Results: Compared to healthy children, the qBEI analyses in transplant recipients prior BP revealed an increase in the most frequently occurring calcium concentration (+2.9%, P=0.001;+3.5%, P=0.014), in the portion of fully mineralized bone (fivefold; 10-fold, both PPP=0.47; cortical bone: 21.4% after BP vs 22.0% prior BP, P=0.56) except in one patient with abnormally low bone matrix mineralization and increased indices of bone turnover that normalized after treatment. Accumulation of mineralized cartilage was observed in the bone tissue after BP. Conclusions: The abnormally high bone matrix mineralization in transplant recipients, consistent with serum and histomorphometric outcomes, indicates a history of low bone turnover with accumulation of fully mineralized bone packets. The increased heterogeneity of mineralization suggests local alterations in mineralization kinetics. This may be linked to dysfunctional osteocytes that accumulate within the bone matrix during organ failure and concomitant glucocorticoid and immunosuppressive medication. BP does not further increase bone matrix mineralization, however the presence of mineralized cartilage warrants further clarifications. The authors have no conflicts of interest. Disclosure: The authors declared no competing interests.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
G[alpha]11-Phe220Ser loss-of-function mutation causes familial hypocalciuric hypercalcemia type-2 (FHH2) by disrupting a hydrophobic cluster critical for G-protein signaling
Mutations of the calcium-sensing receptor (CaSR), G-protein alpha-11 subunit (Gα11), and adaptor protein-2 sigma subunit (AP2σ) resulting in a loss-of-function, cause familial hypocalciuric hypercalcemia types 1-3 (FHH1-3), respectively. We investigated a family with FHH (four affected and two unaffected members) for CaSR, Gα11 and AP2σ mutations, and identified a heterozygous Gα11 missense mutation, Phe220Ser, which is predicted to disrupt a cluster of hydrophobic residues that are important for G-protein/G-protein coupled receptor interactions. Gα11, which acts downstream of the CaSR, activates phospholipase C (PLC) leading to two predominant signal outputs: intracellular calcium (Ca2+i) release; and activation of the extracellular-signal regulated kinase (ERK) mitogen-activated protein kinase (MAPK) pathway. We assessed the effects of the Gα11 mutation on signalling by expressing Gα11-wild-type Phe220, and three Gα11-mutants: Ser220, detected in the FHH2 kindred; and engineered mutants, Ala220 (a hydrophobic residue); and, Glu220 (a non-hydrophobic residue), in HEK293 cells stably expressing CaSR. Ca2+i responses to extracellular calcium (Ca2+e) were assessed using a Fluo-4 fluorescent assay and an NFAT-response element-containing luciferase reporter that measures Ca2+i–induced gene expression; and MAPK responses assessed using a phospho-ERK (pERK) AlphaScreen assay and a serum-response element (SRE)-containing luciferase reporter that measures ERK-induced gene expression. Mutation of Phe220 to the non-hydrophobic Ser220 and Glu220 residues, but not the hydrophobic residue, Ala220, significantly impaired Gα11 signalling via PLC-Ca2+i and ERK/MAPK pathways. Thus, Ser220 and Glu220, when compared to wild-type (Phe220) and Ala220 led to: a rightward shift of the dose-response curves of Ca2+i responses to Ca2+e with increased mean half-maximal concentration (EC50) values; reductions in NFAT reporter responses; impaired pERK responses; and reductions in SRE reporter activity. Thus, we have identified a novel Gα11 mutation, Phe220Ser, causing FHH2, and have demonstrated the importance of the hydrophobic Phe220 residue, which forms part of a cluster, for G-protein signaling via PLC-Ca2+i and ERK/MAPK pathways.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
G[alpha]11-Phe220Ser loss-of-function mutation causes familial hypocalciuric hypercalcemia type-2 (FHH2) by disrupting a hydrophobic cluster critical for G-protein signaling
Mutations of the calcium-sensing receptor (CaSR), G-protein alpha-11 subunit (Gα11), and adaptor protein-2 sigma subunit (AP2σ) resulting in a loss-of-function, cause familial hypocalciuric hypercalcemia types 1-3 (FHH1-3), respectively. We investigated a family with FHH (four affected and two unaffected members) for CaSR, Gα11 and AP2σ mutations, and identified a heterozygous Gα11 missense mutation, Phe220Ser, which is predicted to disrupt a cluster of hydrophobic residues that are important for G-protein/G-protein coupled receptor interactions. Gα11, which acts downstream of the CaSR, activates phospholipase C (PLC) leading to two predominant signal outputs: intracellular calcium (Ca2+i) release; and activation of the extracellular-signal regulated kinase (ERK) mitogen-activated protein kinase (MAPK) pathway. We assessed the effects of the Gα11 mutation on signalling by expressing Gα11-wild-type Phe220, and three Gα11-mutants: Ser220, detected in the FHH2 kindred; and engineered mutants, Ala220 (a hydrophobic residue); and, Glu220 (a non-hydrophobic residue), in HEK293 cells stably expressing CaSR. Ca2+i responses to extracellular calcium (Ca2+e) were assessed using a Fluo-4 fluorescent assay and an NFAT-response element-containing luciferase reporter that measures Ca2+i–induced gene expression; and MAPK responses assessed using a phospho-ERK (pERK) AlphaScreen assay and a serum-response element (SRE)-containing luciferase reporter that measures ERK-induced gene expression. Mutation of Phe220 to the non-hydrophobic Ser220 and Glu220 residues, but not the hydrophobic residue, Ala220, significantly impaired Gα11 signalling via PLC-Ca2+i and ERK/MAPK pathways. Thus, Ser220 and Glu220, when compared to wild-type (Phe220) and Ala220 led to: a rightward shift of the dose-response curves of Ca2+i responses to Ca2+e with increased mean half-maximal concentration (EC50) values; reductions in NFAT reporter responses; impaired pERK responses; and reductions in SRE reporter activity. Thus, we have identified a novel Gα11 mutation, Phe220Ser, causing FHH2, and have demonstrated the importance of the hydrophobic Phe220 residue, which forms part of a cluster, for G-protein signaling via PLC-Ca2+i and ERK/MAPK pathways.
- 1 January 2011
- Vol. 127 (9) , 921-9
[New diagnostic criteria for pediatric osteoporosis--spinal compression fractures are an underdiagnosed problem].
Osteoporosis may be associated with many pediatric conditions. Chronically ill children constitute a special risk group. Diagnosis of osteoporosis in children is challenging; contrary to adults, the diagnosis requires proof of susceptibility to fractures in addition to low bone mineral density. Vertebral fractures without high-energy injury in children are usually indicative of increased bone fragility. In chronically ill children, these fractures are surprisingly common and often asymptomatic.
- 1 January 2011
- Vol. 127 (9) , 921-9
[New diagnostic criteria for pediatric osteoporosis--spinal compression fractures are an underdiagnosed problem].
Osteoporosis may be associated with many pediatric conditions. Chronically ill children constitute a special risk group. Diagnosis of osteoporosis in children is challenging; contrary to adults, the diagnosis requires proof of susceptibility to fractures in addition to low bone mineral density. Vertebral fractures without high-energy injury in children are usually indicative of increased bone fragility. In chronically ill children, these fractures are surprisingly common and often asymptomatic.
- Open Access
- 1 October 2009
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 24 (10) , 1699-1708
Bone Health in Children and Adolescents After Renal Transplantation
The basis for lifelong bone health is established in childhood and adolescence. Whereas pediatric renal transplant (RTx) patients are at risk for impaired bone mass gain and fractures, scarce data on this subject are available. We performed a cross‐sectional and longitudinal study of bone health in a national cohort of 106 pediatric RTx patients (median age, 12.6 yr; median follow‐up, 5.1 yr after RTx). The patients underwent clinical evaluation, DXA for BMD, and spinal imaging for vertebral fractures. In longitudinal analysis, the median lumbar spine BMD Z‐score was lowest (median, −1.0) at 1 yr postoperatively but increased to a peak value of −0.2 at 5 yr. In boys, the lumbar spine BMD Z‐score increased also during puberty but decreased in girls. In cross‐sectional analysis, the lumbar spine, hip, and whole body BMD Z‐scores were < −2 SD in 4%, 6%, and 6% of the patients, respectively. Sixteen percent had sustained peripheral fractures, and 8% had vertebral fractures. Female sex and age >15 yr (OR, 56.26; 95% CI, 5.17–611.82; p = 0.0007) as well as high plasma PTH levels (OR, 4.03; 95% CI, 1.37–11.85; p = 0.009) were significant predictors for low BMD. Three‐year cumulative glucocorticoid dose, outside the immediate post‐RTx years, was not associated with BMD parameters. The observed BMD results were satisfactory. However, the high (8%) prevalence of vertebral fractures warrants careful evaluation of bone health in these patients.
- 1 October 2009
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 24 (10) , 1699-1708
Open AccessBone Health in Children and Adolescents After Renal Transplantation
The basis for lifelong bone health is established in childhood and adolescence. Whereas pediatric renal transplant (RTx) patients are at risk for impaired bone mass gain and fractures, scarce data on this subject are available. We performed a cross‐sectional and longitudinal study of bone health in a national cohort of 106 pediatric RTx patients (median age, 12.6 yr; median follow‐up, 5.1 yr after RTx). The patients underwent clinical evaluation, DXA for BMD, and spinal imaging for vertebral fractures. In longitudinal analysis, the median lumbar spine BMD Z‐score was lowest (median, −1.0) at 1 yr postoperatively but increased to a peak value of −0.2 at 5 yr. In boys, the lumbar spine BMD Z‐score increased also during puberty but decreased in girls. In cross‐sectional analysis, the lumbar spine, hip, and whole body BMD Z‐scores were < −2 SD in 4%, 6%, and 6% of the patients, respectively. Sixteen percent had sustained peripheral fractures, and 8% had vertebral fractures. Female sex and age >15 yr (OR, 56.26; 95% CI, 5.17–611.82; p = 0.0007) as well as high plasma PTH levels (OR, 4.03; 95% CI, 1.37–11.85; p = 0.009) were significant predictors for low BMD. Three‐year cumulative glucocorticoid dose, outside the immediate post‐RTx years, was not associated with BMD parameters. The observed BMD results were satisfactory. However, the high (8%) prevalence of vertebral fractures warrants careful evaluation of bone health in these patients.
- 15 February 2007
- Vol. 34 (4) , 831-6
Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis.
To evaluate bone health and growth and their correlates in glucocorticoid (GC)-treated pediatric patients with juvenile idiopathic arthritis (JIA). Consecutive patients with a history of JIA for >or= 2 years and systemic GC treatment for >or= 3 months were assessed for bone health and its determinants. Areal bone mineral density (aBMD) and vertebral body morphology were assessed with DEXA; Z scores were adjusted for calendar and bone age. Values were correlated with biochemistry, disease activity, and medications. Sixty-two patients (43 female; median age 11.8 yrs, median disease duration 5.6 yrs) were included. The median duration of GC treatment was 24 months and the median cumulative dose (as prednisolone) was 2.2 g. Four patients had had fractures. The median bone age-corrected aBMD Z score was -0.4 (range -2.9 to +1.8) for lumbar spine and -0.1 (range -2.1 to +2.4) for femoral neck. Abnormal vertebral morphology was observed in 6 patients (10%). No correlation was found between aBMD and disease characteristics or cumulative GC dose. The median Z score for height was +0.1 (range -2.9 to +1.5) and the median height-adjusted weight +4% (range -17% to +40%). Our study showed low prevalence of osteoporosis and normal growth in children with JIA. However, asymptomatic vertebral fractures were observed in 10% of the patients, indicating that DEXA alone may not be sufficient when evaluating bone health in these children. Osteoporosis still remains a concern in children with GC-treated JIA.
- 15 February 2007
- Vol. 34 (4) , 831-6
Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis.
To evaluate bone health and growth and their correlates in glucocorticoid (GC)-treated pediatric patients with juvenile idiopathic arthritis (JIA). Consecutive patients with a history of JIA for >or= 2 years and systemic GC treatment for >or= 3 months were assessed for bone health and its determinants. Areal bone mineral density (aBMD) and vertebral body morphology were assessed with DEXA; Z scores were adjusted for calendar and bone age. Values were correlated with biochemistry, disease activity, and medications. Sixty-two patients (43 female; median age 11.8 yrs, median disease duration 5.6 yrs) were included. The median duration of GC treatment was 24 months and the median cumulative dose (as prednisolone) was 2.2 g. Four patients had had fractures. The median bone age-corrected aBMD Z score was -0.4 (range -2.9 to +1.8) for lumbar spine and -0.1 (range -2.1 to +2.4) for femoral neck. Abnormal vertebral morphology was observed in 6 patients (10%). No correlation was found between aBMD and disease characteristics or cumulative GC dose. The median Z score for height was +0.1 (range -2.9 to +1.5) and the median height-adjusted weight +4% (range -17% to +40%). Our study showed low prevalence of osteoporosis and normal growth in children with JIA. However, asymptomatic vertebral fractures were observed in 10% of the patients, indicating that DEXA alone may not be sufficient when evaluating bone health in these children. Osteoporosis still remains a concern in children with GC-treated JIA.